(Q43915113)

28 November 2017

title

Does behavioral improvement with haloperidol or trazodone treatment depend on psychosis or mood symptoms in patients with dementia? (English)

1 reference

28 November 2017

1 reference

1 reference

Sultzer DL

1

1 reference

28 November 2017

Gray KF

2

1 reference

28 November 2017

Gunay I

3

1 reference

28 November 2017

Wheatley MV

4

1 reference

28 November 2017

Mahler ME

5

1 reference

28 November 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

Journal of the American Geriatrics Society

28 November 2017

published in

1 reference

28 November 2017

volume

49

1 reference

28 November 2017

issue

10

1 reference

28 November 2017

page(s)

1294-1300

1 reference

Assessment of cognitive, psychiatric, and behavioral disturbances in patients with dementia: the Neurobehavioral Rating Scale

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2001.49256.X

The spectrum of behavioral changes in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2001.49256.X

The course of psychopathologic features in mild to moderate Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2001.49256.X

The relationship between dementia and elder abuse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2001.49256.X

Correlates of depression and burden for informal caregivers of patients in a geriatrics referral clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2001.49256.X

Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2001.49256.X

Effective behavioral interventions for decreasing dementia-related challenging behavior in nursing homes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2001.49256.X

Management of dementia-related behavioral disturbances: a nonpharmacologic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2001.49256.X

Management of verbally disruptive behaviors in nursing home residents

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2001.49256.X

Withdrawal from controlled carbamazepine therapy followed by further carbamazepine treatment in patients with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2001.49256.X

Pharmacologic treatment of agitation in dementia: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2001.49256.X

A metaanalysis of controlled trials of neuroleptic treatment in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2001.49256.X

A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2001.49256.X

Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2001.49256.X

A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2001.49256.X

Efficacy and tolerability of carbamazepine for agitation and aggression in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2001.49256.X

The efficacy and tolerability of divalproex sodium in elderly demented patients with behavioral disturbances

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2001.49256.X

An open trial of valproate for agitation in geriatric neuropsychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2001.49256.X

The use of selective serotonin reuptake inhibitors for depression and psychosis complicating dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2001.49256.X

An open pilot study of citalopram for behavioral disturbances of dementia. Plasma levels and real-time observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2001.49256.X

A description of agitation in a nursing home

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2001.49256.X

Development of a Rating Scale for Primary Depressive Illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2001.49256.X

Relationship of aggressive behavior to other neuropsychiatric symptoms in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2001.49256.X

Psychotic symptoms and physically aggressive behavior in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2001.49256.X

Clinical features and pharmacologic treatment of behavioral symptoms of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2001.49256.X

The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2001.49256.X

Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2001.49256.X

CSF biochemistries, glucose metabolism, and diurnal activity rhythms in alcoholic, violent offenders, fire setters, and healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2001.49256.X

Possible neurotransmitter basis of behavioral changes in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2001.49256.X

Platelet tritiated imipramine binding and MAO activity in Alzheimer's disease patients with agitation and delusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2001.49256.X

Fenfluramine challenge test as a marker of serotonin activity in patients with Alzheimer's dementia and agitation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2001.49256.X

The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2001.49256.X

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2001.49256.X

10.1046/J.1532-5415.2001.49256.X

21 January 2018

Identifiers

DOI

1 reference

28 November 2017

1 reference